Nov 21, 2024

EP-PerMed pre-announced its first call - “Pharmacogenomic Strategies for Personalised Medicine “!

The European Partnership for Personalised Medicine, EP PerMed will launch the joint transnational call 2025 “Pharmacogenomic Strategies for Personalised Medicine”, co-funded by the EU, to fund multinational innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe in this field. The available budget for this call is 35 Mio. € (approx.).

The overall objectives of the JTC2025 will be to

Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:
- identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
- validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
- use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Research projects in all disease areas will be welcome.

Timeline and eligibility criteria:

Mid of December, 2024 – publication of the Call
09^th January 2025 – Information day
18^th February 2025 – pre-proposal submission
17^th June 2025 –full-proposal submission
min 3 partner from 3 participating countries

Participating countries:

Austria (AT), Belgium (BE), Czech Republic (CZ), Denmark (DK), Estonia (EE), Finland (FI), France (FR), Germany (DE), Greece (GR), Hungary (HU), Iceland (IS), Ireland (IE), Israel (IL), Italy (IT), Latvia (LV), Lithuania (LT), Luxembourg (LU), Norway (NO), Poland (PO), Portugal (PT), Spain (ES), Sweden (SE), Türkiye (TR)